[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-sequelae\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-sequelae":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,41,74,101,129,151,178,200,230,260,281,308,336,357,385,409,430,460,487,517,542,567,599],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100376976","imaging-post-stroke-recovery-using-meg-to-evaluate-cognition-100376976",false,"NCT04188522","Imaging Post-Stroke Recovery: Using MEG to Evaluate Cognition","Imaging the Network: Using MEG to Determine the Pathophysiology Underlying Post-Stroke Cognitive Impairment","Inclusion Criteria:\n\n1. Adults (≥18 years) admitted to Bayview Medical Center Neurology.\n2. Evidence of acute ischemic stroke (CT or MRI)- lacunar stroke or branch occlusion (M3\u002FA3\u002FP3 or smaller) OR NIHSS ≤ 8 on admission.\n3. Competent speaker of English (by self or family report) prior to stroke.\n4. Return for follow-up 4-6 weeks post event (+\u002F- 4 wks).\n5. Cognitive deficits present on initial testing.\\*\\* unique to MEG study\n6. Willing to travel to the University of Maryland twice for MEG.\\*\\* unique to MEG study\n7. Fully independent functionally and able to travel to the University of Maryland unassisted.\\*\\* unique to MEG study\n\nExclusion Criteria:\n\n1. Primary intracerebral hemorrhage- as evidenced by blood on head CT or MRI.\n2. Previous neurological disease (e.g., dementia, multiple sclerosis, prior symptomatic stroke). Incidental asymptomatic lacunar strokes found on imaging will not be excluded as prior disease.\n3. Uncorrected hearing or visual loss.\n4. Large vessel occlusion.\n5. Presence of any of the following that would lead to significant artifact on MEG: cardiac pacemaker, intracranial clips, metal implants, or external clips within 10mm of the head, metal in the eyes.\\*\\* unique to MEG study\n6. Claustrophobia, obesity, and\u002For any other reason leading to difficulty staying in the MEG for up to 1 hour.\\*\\* unique to MEG study\n7. For controls- clinical history of stroke or other neurological dysfunction (seizure, multiple sclerosis, etc.); psychiatric disease","ALL","18 Years","100 Years",{"count":20,"type":21},55,"ESTIMATED","OBSERVATIONAL","This is a study using magnetoencephalography (MEG) to look at recovery in those with minor stroke. The investigators know that these individuals report difficulties in attention, concentration, multi-tasking, energy level, and processing speed that appear to be independent of lesion size or location. The underlying pathophysiology is unclear; however, anecdotally, many individuals are significantly improved by 6 months post-stroke. One hypothesis is that a single lesion, regardless of size, may disrupt the classic neural networks required for cognitive function. The investigators are currently collecting data to better characterize these difficulties and stroke patients' recovery as part of a previously approved recovery study. In this sub-study, the investigators propose to add MEG at 1 and 6 months in a subset of individuals with small: 1) subcortical, and 2) cortical lesions. The investigators will partner with colleagues at the University of Maryland (College Park), who are well experienced with MEG to conduct this research. In addition a control population of age-similar individuals will be recruited for comparison. Cerebral activation patterns of individuals with stroke versus controls will be compared, both across patients with stroke at a given time point, and within subjects from 1 to 6 months to determine the association of abnormal activation with cognitive dysfunction and recovery.\n\n\\*\\*The investigators have recently extended follow-up by adding an additional assessment at 12 months and will enroll additional participants (up to 40 patients with minor stroke, 15 age-similar controls).",[25,26,27],"Stroke","Stroke Sequelae","Stroke\u002FBrain Attack","RECRUITING","2026-06-03",{"date":31,"type":32},"2026-06-05","ACTUAL",{"date":34,"type":32},"2018-07-01",{"date":36,"type":21},"2027-06-30",{"name":38,"class":39},"Johns Hopkins University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100594442","young-stroke-service-deep-phenotyping-exploring-recovery-in-young-adult-survivors-of-stroke-100594442","NCT07019493","Young Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke","Inclusion Criteria:\n\n1. Between 18 and 55 years.\n2. Within one month of acute stroke confirmed with standard of care brain imaging or clinical diagnosis or for those for whom recruitment \\\u003C1 month of stroke is not possible they may be recruited to participate within 3-months of stroke\n\nExclusion Criteria:\n\n1. Severe, intercurrent or progressive illness likely to EITHER\n\n   1. Have a prognosis for survival under 24 months; OR\n   2. In the opinion of the investigator will mask the importance to the individual participant data (e.g. severe MS, dementia, etc)\n2. Major psychiatric condition requiring medical intervention","55 Years",{"count":49,"type":21},100,"The Investigators are running a small, early-phase research study across several hospitals in Melbourne, Australia. The study will involve up to 100 young adults between the ages of 18 and 55 who have had a stroke. The goal is to test how practical it is to carry out a detailed health assessment process-called \"deep phenotyping\"-with this group.\n\nThis process involves collecting a wide range of information and samples from stroke survivors to better understand each participant's condition. The Investigators will look at how well this approach works in practice, including how easy it is to use, whether it's done consistently, and how acceptable it is to participants.\n\nAt the same time, the Investigators will also explore how different factors-such as biological markers (biomarkers), age, sex, type of stroke, lifestyle, and environment-might be related to stroke recovery. This pilot study will prepare for larger studies in the future.",[52,25,53,54],"Stroke Patients","Stroke; Sequelae","Young Adults",[56,57,58,59,60,61,62,63],"recovery","young stroke","ischemic stroke","hemorrhagic stroke","poststroke fatigue","post-stroke cognitive impairment","function","mood","2026-04-16",{"date":66,"type":32},"2026-04-21",{"date":68,"type":32},"2025-07-19",{"date":70,"type":21},"2027-12",{"name":72,"class":39},"The Florey Institute of Neuroscience and Mental Health",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100631137","effects-of-different-frequency-electroacupuncture-on-suprahyoid-muscles-in-post-stroke-dysphagia-efficacy-and-neural-networks-100631137","NCT07496762","Effects of Different-Frequency Electroacupuncture on Suprahyoid Muscles in Post-Stroke Dysphagia: Efficacy and Neural Networks","Inclusion Criteria:\n\n* Diagnosis: Patients diagnosed with cerebral infarction confirmed by CT or MRI.\n* Dysphagia Screening: Presence of varying degrees of dysphagia as screened by the Water Swallow Test (WST).\n* Clinical Status: Conscious and stable vital signs, with the ability to cooperate with the treatment.\n* Age: Aged between 18 and 80 years.\n* Consent: Signed informed consent form obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n* Dysphagia Etiology: Patients with dysphagia caused by etiologies other than cerebral infarction.\n* MRI Contraindications: Patients with metal implants or pacemakers in the body (contraindications for MRI).\n* Bleeding Risk: Patients with bleeding tendencies or coagulation disorders.\n* Blood Pressure: Patients with uncontrolled hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 120 mmHg).\n* Organ Failure: Patients with severe failure of vital organs (e.g., heart, liver, or kidney failure).\n* Disease Severity: Patients with critical or life-threatening stroke conditions.\n* Cooperation: Patients unable to cooperate with the treatment due to severe cognitive impairment, aphasia, or other reasons.","80 Years",{"count":82,"type":21},90,"INTERVENTIONAL",[85],"NA","This randomized controlled study in patients with post-stroke dysphagia aims to determine the optimal stimulation frequency of electroacupuncture of the suprahyoid muscles and to elucidate the underlying neural mechanisms. Participants will be assigned to low-frequency (2 Hz), medium-frequency (50 Hz), or high-frequency (100 Hz) electroacupuncture groups. Therapeutic efficacy will be assessed using the Kubota water-drinking test, videofluoroscopic swallowing study (VFSS), and ultrasonography to identify the optimal frequency. In parallel, diffusion tensor imaging (DTI) will be used to evaluate changes in fiber connectivity between swallowing-related cortical regions (bilateral precentral gyrus, insula, supramarginal gyrus, and frontal lobe) and the medullary nucleus tractus solitarius, thereby exploring neural network remodeling and providing mechanistic evidence to inform clinical practice.",[26,88,89,90],"Deglutition Disorders","Acupuncture Therapy","Electroacupuncture",[26,88,89,90],"NOT_YET_RECRUITING","2026-03-23",{"date":95,"type":32},"2026-03-27",{"date":66,"type":21},{"date":98,"type":21},"2028-12-21",{"name":100,"class":39},"Kaili Chen",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":83,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":40},"100552159","decoding-motor-imagery-from-non-invasive-brain-recordings-as-a-prerequisite-for-innovative-motor-rehabilitation-therapies-100552159","NCT06469463","Decoding Motor Imagery From Non-invasive Brain Recordings as a Prerequisite for Innovative Motor Rehabilitation Therapies","MODECO","Inclusion Criteria:\n\nControl group:\n\n* Healthy subjects with age\\> 18, male or female.\n* Right handed (Due to the fact that unlike right-handed people, left-handed people tend to have more complicated somatotopic organization of the motor cortex, we will avoid confounding observed differences to differences attributable to anatomic factors).\n* Registered with the French healthcare system.\n* Motivated to participate in the study.\n* Normal or corrected vision.\n* Adequate knowledge of French language to be able to follow directions.\n* Subjects must be able to listen and understand the study instructions.\n* Subjects must be able to give written informed consent before participation.\n* No history of neurological or psychiatric disease.\n* No physical disability of the arms or wrists.\n* No use of drugs affecting the central nervous system or self-reported abuse of any drugs.\n\nPatient group :\n\n* Male or female stroke patients over 18 years old.\n* Stroke patients must be not be in the acute phase of stroke.\n* Right-handed.\n* Having motor disorders in at least one of the upper limbs following the stroke, possibly with moderate accompanying deficits but no cognitive deficits.\n* Entitled to a social security scheme.\n* Motivated to participate in the study.\n* Having normal or corrected vision.\n* Having a sufficient understanding of the French language to be able to follow directions.\n* Able to listen and understand study instructions.\n* Able to give their written informed consent before participating.\n\nExclusion Criteria:\n\n* Subjects with characteristics incompatible with MEG and MRI :\n\n  1\\. Claustrophobia.\n* Subjects with motor impairment (only applies to control group), severe traumatic brain injury.\n* Subjects with chronic stroke (applies to both groups).\n* Subjects history of skin disease or skin allergies (multiple or severe).\n* Subjects who:\n\n  1. have had an MRI within 2 weeks prior to the experiment.\n  2. have implanted materials (any dental apparatus containing metal including or root canals or any metallic object, pacemaker, cochlear implanted in the body).\n* Subjects working with metals in their professional lives.\n* Pregnant or lactating women Pregnant or lactating women (check with a urinary test).\n* Subjects who are not able to tolerate sitting for longer than 2 hours (the estimated length of an experimental session is about 2h30mins).\n* Subjects with alcohol dependence (no consumption of alcohol or drugs at least 24 hours prior to the day of experiments).\n* Subjects currently taking a medication that may have a strong effect on MEG or EEG recordings (e.g., antidepressants, stimulant medication, etc).\n* Subjects who, in the opinion of the investigator, are not able or willing to comply with the protocol.\n* Persons under guardianship or curatorship.\n* Persons in emergency situations who cannot give their consent.\n* Subjects under 18 years of age.\n* Subjects under legal protection measures.\n* Volunteers with contraindications to MEG examination\n* Pacemaker.\n* Implanted pump including insulin pump.\n* Neurostimulator.\n* Cochlear implants or other hearing aids.\n* Metal prosthesis.\n* Intracerebral \u002F surgical aneurysm clips.\n* Ocular or cerebral ferromagnetic foreign bodies in the upper body.\n* Neurosurgical ventriculoperitoneal shunt valves.",true,{"count":110,"type":21},35,[85],"Seminal studies in motor neuroscience involving healthy subjects have revealed time-locked changes in induced power within specific frequency bands. Brain recordings were shown to exhibit a gradual reduction in signal power, relative to baseline, in the mu and beta frequency bands during an action or during motor imagery: the event-related desynchronization (ERD). This is considered to reflect processes related to movement preparation and execution and is particularly pronounced in the contralateral sensorimotor cortex. Shortly following the completion of the task, a relative increase in power, the event-related synchronization (ERS), could be observed in the beta band. ERS is thought to reflect the re-establishment of inhibition in the same area.\n\nEver since the characterization of the ERD and ERS phenomena, there has been little to no discussion in the field of non-invasive Brain Computer Interfaces (BCI) as to whether these features accurately capture the task-related modulations of brain activity. Recent studies in neurophysiology have demonstrated that the ERD and ERS patterns only emerge as a result of averaging signal power over multiple trials. On a single trial level, beta band activity occurs in short, transient events, bursts, rather than as sustained oscillations. This indicates that the ERD and ERS patterns reflect accumulated, time-varying changes in the burst probability during each trial. Thus, beta bursts may carry more behaviourally relevant information than averaged beta band power. Studies in humans involving arm movements have established a link between the timing of sensorimotor beta bursts and response times before movement, as well as behavioural errors post-movement. Beta burst activity in frontal areas has also been shown to correlate with movement cancellation and recent studies show that activity at the motor unit level also occurs in a transient manner, which is time-locked to sensorimotor beta bursts.\n\nAlthough beta burst rate has been shown to carry significant information, it still comprises a rather simplistic representation of the underlying activity. Indeed, complex burst waveforms are embedded in the raw signals, and can be characterized by a stereotypical average shape with large variability around it. The waveform features are neglected in standard BCI approaches, because conventional signal processing methods generally presuppose sustained, oscillatory and stationary signals, and are thus inherently unsuitable for analysing transient activity.\n\nIn contrast to beta, activity in the mu frequency band is oscillatory even in single trials. This activity is typically analysed using time-frequency decomposition techniques, which assume that the underlying signal is sinusoidal. However, there is now growing consensus that oscillatory neural activity is often non-sinusoidal and that the raw waveform shape can be informative of movement.\n\nIn this project, the design of a subject-specific neurophysiological model to guide motor BCI training will be optimized using Magnetic Resonance Imaging (MRI) and Magnetoencephalography (MEG) for high spatial and biophysical specificity in the experimental group. Anatomical MR volumes will be used to design and 3D-print an individual head cast that will be used in the MEG scanner to stabilize the head position and minimize movements. This high-precision approach (hpMEG) has been proven to significantly improve source localization up to the level of distinguishing laminar activity, which makes it superior to EEG recording technique. An individualized hpMEG approach, as well as the widely adopted EEG, will be used to study bursts of oscillatory activity in the beta and mu frequency bands related to motor imagery and motor execution. hpMEG will yield subject-specific models of motor imagery that will be used to constrain online decoding of EEG data. This approach will be applied and validated on a group of healthy adult subjects and will then be compared against another feasibility group of patients and age-matched healthy participants. The proposed approach will be compared with a classic EEG-based BCI approach.\n\nThe information will be used to optimally guide subsequent EEG-based BCI training in the control group. After a thorough investigation in healthy subjects in this project, the feasibility of the approach will be evaluated in a few stroke patients with upper-limb motor deficits. Tasks 1.1 and 1.2 aim to develop subject-specific generative models decoding movement onset and offset, the type of movement, as well as finely discretized movement amplitude during both real and imagined wrist extensions\u002Fflexions. Task 1.2 investigates how lesions of patients alter our ability to decode attempted wrist movements.",[26,114,115],"Motor Imagery","Upper Limb Deficit",[117,118,119,120],"Motor imagery","motor rehabilitation","magnetoencephalography","electroencephalography","2026-03-17",{"date":123,"type":32},"2026-03-19",{"date":121,"type":32},{"date":126,"type":21},"2028-08",{"name":128,"class":39},"Hospices Civils de Lyon",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":83,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100538341","home-tele-rehabilitation-therapy-for-vascular-dementia-100538341","NCT06289569","Home Tele Rehabilitation Therapy for Vascular Dementia","Inclusion Criteria:\n\n* Symptomatic ischemic or hemorrhagic stroke verified by computerized axial tomography or magnetic resonance imaging\n* at least 6 months post stroke\n* At least some active movement in the affected upper extremity (MRS 1 or more in shoulder elbow or wrist)\n* Ability to provide informed consent, or LAR able to provide consent\n* Expressed willingness to comply with all study procedures and attend all study-related visits for both the patient and at least one caregiver.\n* Age ≥ 18.\n* Ability to follow one-step commands.\n* Community-dwelling with transportation to evaluation sessions.\n* Ability to operate the therapy system with minimal assistance, including sufficient corrected vision to perceive objects from a distance of 5 feet.\n* Modified Ashworth Scale Score 3 or less in the involved upper extremity\n* Passive range of motion within functional ranges at the shoulder, elbow, wrist and hand\n\nExclusion Criteria:\n\n* Patients with history of severe alcohol or drug abuse, psychiatric illnesses like severe depression, poor motivational capacity, or severe language disturbances, particularly of receptive nature or with serious cognitive deficits (defined as unable to follow study instructions even with help from caregiver).\n* Patients with bilateral paresis, or weakness or sensory damage due to peripheral causes (e.g. peripheral nerve injury, muscle or orthopedic injury etc.)\n* Patients with severe uncontrolled medical problems that would render intensive rehabilitation unfeasible or unsafe (e.g. cardiovascular disease, unstable cardiac arrhythmia, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer or renal disease, any kind of end-stage pulmonary or cardiovascular disease, or a deteriorated condition due to age, epilepsy or others).\n* Concurrent participation in other experimental upper extremity rehabilitation trials that would interfere with results.\n* Non-English-speaking individuals will only be eligible if they can provide the appropriate translator for all the sessions of the study as no funding is available to pay for such services. However, we plan to include them once funding has been secured in the subsequent larger trial.\n* Pregnancy\n* Prisoners","110 Years",{"count":137,"type":21},120,[85],"To determine whether the home telerehabilitation therapy is feasible and lessens caregiver burden in chronic stroke patients with and without vascular dementia (VaD)",[141,26],"Dementia, Vascular","2026-02-27",{"date":144,"type":32},"2026-03-02",{"date":146,"type":32},"2024-12-14",{"date":148,"type":21},"2028-04-01",{"name":150,"class":39},"The Methodist Hospital Research Institute",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":83,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":40},"100577350","a-novel-wrist-wearable-sensor-system-to-promote-hemiparetic-upper-extremity-use-in-subacute-stroke-survivors-100577350","NCT06797154","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Subacute Stroke Survivors","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Subacute Stroke Survivors","Inclusion Criteria:\n\n* Male or female, 18-85 years of age at the time of enrollment\n* Anterior circulation ischemic stroke at least 1 month and no more than 6 months prior to study enrollment;\n* Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;\n* Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3step command) ;\n* Owning a smartphone (iOS or Android) and being familiar and comfortable with and owning a tablet or smartphone\n* SAFE score equal or greater than 5\n\nExclusion Criteria:\n\n* Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;\n* Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see the feedback on the app screen (as assessed with the Mesulum cancellation test);\n* Individuals with open wounds or recent fracture (less than 3 months) in the upper extremity, fragile skin or active infection;\n* Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;\n* Diagnosis of other neurological disease; (i.e., Parkinson's disease, multiple sclerosis, ...);\n* Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening;\n* Not understanding spoken or written English;\n* Contralateral motor deficits as assessed by clinical examination;\n* Brainstem and cerebellar stroke.","85 Years",{"count":160,"type":21},88,[85],"The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in subacute stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).",[25,26,164],"Hemiparesis;Poststroke\u002FCVA",[166,167,168],"StrokeWear","Biosensics","Behavioral Intervention","2025-11-21",{"date":171,"type":32},"2025-11-28",{"date":173,"type":32},"2025-08-08",{"date":175,"type":21},"2026-08-31",{"name":177,"class":39},"Spaulding Rehabilitation Hospital",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":158,"enrollmentInfo":185,"targetDuration":4,"studyType":83,"phases":187,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":40},"100487423","phase-2-novel-wrist-sensor-system-to-promote-hemiparetic-arm-use-in-home-daily-life-of-chronic-stroke-survivors-100487423","NCT05626894","Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Chronic Stroke Survivors","Inclusion Criteria:\n\n* Male or female, 18-85 years of age at the time of enrollment;\n* Anterior circulation ischemic stroke at least 6 months and up to 5 years prior to study enrollment;\n* Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;\n* Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3 step command);\n* Being familiar and comfortable with the use of a tablet or smartphone.\n\nExclusion Criteria:\n\n* Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;\n* Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see feedback on the app screen (as assessed with the star cancellation test);\n* Individuals with open wounds or recent fracture (less than 3 months) in the UE, fragile skin or active infection as evaluated by the study therapist;\n* Individuals currently enrolled in a UE rehabilitation program (i.e., OT, research study)\n* Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;\n* Diagnosis of other neurological disease (i.e., Parkinson's disease, multiple sclerosis, ...);\n* Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening as assessed by the study therapist;\n* Not understanding spoken or written English;\n* Recent (less than 3 months) Botox injection in the UE or plan to undergo injections during the study timeline;\n* Contralateral motor deficits as assessed by clinical examination;\n* Brainstem and cerebellar stroke.",{"count":186,"type":21},32,[188],"PHASE2","The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in chronic stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).",[25,26,164],[166,192,193],"BioSensics","Behavioral intervention",{"date":171,"type":32},{"date":196,"type":32},"2025-03-20",{"date":198,"type":21},"2026-09-30",{"name":177,"class":39},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":83,"phases":210,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":228,"locationsCount":40},"100601636","phase-1-accelerated-rtms-vs-sham-for-stroke-apathy-100601636","NCT07113067","Accelerated rTMS vs. Sham for Stroke Apathy","Accelerated rTMS for Post-stroke Apathy: A Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n* 40 years old or greater\n* Right- or left-hemisphere ischemic or hemorrhagic stroke with at least 6 months chronicity\n* Symptomatic apathy as confirmed by (A) total score on the Apathy Evaluation Scale by the participant or the caregiver\u002Fco-participant (AES) of ≥39\n* Ability to participate in psychometric testing and cognitive tasks\n* Intact cortex at the TMS target site as confirmed by pre-treatment MRI\n* Ability to have a co-participant\u002Fcaregiver who meets the criteria as detailed below.\n\nExclusion Criteria:\n\n* Primary extra-axial hemorrhage (subdural or subarachnoid) without ischemic stroke or intraparenchymal hemorrhage\n* Concomitant neurological disorders affecting motor or cognitive function (e.g. dementia)\n* Moderate or severe global aphasia\n* Visual impairment precluding completion of cognitive tasks\n* Presence of contraindications to MRI or TMS including electrically, magnetically or mechanically activated metal or nonmetal implants such as cardiac pacemaker, intracerebral vascular clips or any other electrically sensitive support system;\n* Pregnancy (to be later confirmed by UPT in any premenopausal female participants)\n* History of a seizure disorder\n* Preexisting scalp lesion, wound, bone defect, or hemicraniectomy\n* Claustrophobia precluding ability to undergo an MRI\n* Active substance use disorder\n* Psychotic disorders\n* Bipolar 1 Disorder\n* Acute suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)30 or suicide attempt in the previous year\n\nFor CO-PARTICIPANT\u002FCAREGIVER:\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Is a reliable informant who has at least weekly contact with the participant and can speak to the participant's cognitive and everyday functioning.\n\nExclusion Criteria:\n\n\\- Unable to engage with study procedures in which Co-Participant input is needed.","40 Years",{"count":209,"type":21},40,[211,188],"PHASE1","Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.",[214,25,26,27,215,216,217],"Apathy","Stroke\u002F Cerebrovascular Accident (Ischemic or Hemorrhagic)","Motivation","Abulia",[219,25,220,214,221,216,217,222],"Depression","Stroke Recovery","TMS","Amotivation","2025-10-21",{"date":225,"type":32},"2025-10-22",{"date":173,"type":32},{"date":36,"type":21},{"name":229,"class":39},"Medical University of South Carolina",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":83,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100609216","clinical-implementation-of-multichannel-functional-electrical-stimulation-device-for-gait-rehabilitation-in-subchronic-stroke-a-feasibility-study-100609216","NCT07211672","Clinical Implementation of Multichannel Functional Electrical Stimulation Device for Gait Rehabilitation in Subchronic Stroke: A Feasibility Study","Effictiveness of Multichannel Functionnal Electrical Motor and Sensorimotor Stimulation for Subchronic Stroke Gait Rehabilitation","Inclusion Criteria:\n\n* First ischemic stroke or first hemorrhagic supratentorial stroke\n* Stroke must be unique\n* Stoke event in the last 12 months but no sooner than 6 months (post subchronic stroke phase)\n* Able to walk with the support of one person and one or multiple walking aids (new functionnal ambulatory classification equal to 1, 2 or 3)\n* Able to tolerate and respond to electrical stimulation(Muscle strength grading level 3 while having the quadriceps stimulated)\n* Willing to delay anti-spastic treatments like botulinic toxins and motor blockers until the end of the rehabilitation period included in the protocol\n\nExclusion Criteria:\n\n* Multiple strokes\n* Does not respond sufficiently to electrical stimulation\n* Contraindication to electrical stimulation\n* Comprehension, psychiatric or cognitive problems that could hamper the protocol\n* Bilateral stroke or subtentorial stroke\n* Able to walk without the support of one person (new functionnal ambulatory clssification equal to 4 or more)\n* Needing help from more than one person to walk (new functionnal ambulatory classification equal to 0)\n* Moderate spasticity in one or more lower body muscle groups (Modified Ashworth Scale Score \\>= 2)",{"count":238,"type":21},5,[85],"The goal of this interventional study is to evaluate the effect of multichannel functionnal electrical stimulation for subchronic stroke gait rehabilitation. The main questions it aims to answer are:\n\n* Does this new therapy help improve walking speed?\n* Evaluate other aspects of therapeutic effectiveness such as different aspects of walking endurance, mobility, postural instability and autonomy.\n* Evaluate physiological aspects of autonomous gait such as spasticity, muscle strength and motor and sensorimotor recovery.\n* Evaluate the acceptability of this new therapy and its effect on quality of life.",[26,242],"Stroke ( 3 Months After Onset)",[244,245,246,247,248,249,250],"Subchronic stroke","Gait","Rehabilitation","Functionnal electrical stimulation","Motor","Sensorimotor","Multichannel","2025-10-01",{"date":253,"type":32},"2025-10-08",{"date":255,"type":21},"2025-10-31",{"date":257,"type":21},"2027-02-28",{"name":259,"class":39},"TOPMED",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":267,"targetDuration":4,"studyType":83,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":40},"100454273","tdcs-to-improve-post-stroke-cognitive-impairment-100454273","NCT05195398","TDCS to Improve Post-Stroke Cognitive Impairment","TIPSCI","Inclusion Criteria:\n\n1. Adults (≥18 years) presenting with neurological symptoms due to acute ischemic stroke (symptom onset within the week prior to admission).\n2. Evidence on brain MRI of acute ischemic stroke (imaging negative strokes and TIAs will be excluded).\n3. Native English speaker (by self-report) prior to stroke.\n4. NIHSS \\\u003C8 at initial follow-up visit (approximately 30 days post-stroke).\n5. mRS 0-2 at initial follow-up visit.\n\nExclusion Criteria:\n\n1. Primary intracerebral hemorrhage- as evidenced by blood on head CT or MRI.\n2. Presence of proximal large vessel occlusion.\n3. Cortical exam findings including aphasia or neglect.\n4. Prior report or history of dementia or undertreated psychiatric illness.\n5. Uncorrected hearing or visual loss.\n6. Inability to attend treatment or follow-up sessions.\n7. Inability to travel to College Park (UMD) for MEG recording sessions.\n8. Presence of any of the following that would lead to significant artifact on MEG: cardiac pacemaker, intracranial clips, metal implants or external clips within 10mm of the head, metal implants in the eyes (unlikely given that all patients will have an MRI and criteria are similar).\n9. Claustrophobia, obesity, and\u002For any other reason leading to difficulty staying in the MEG machine for up to 1 hour.",{"count":268,"type":21},60,[85],"The investigators will conduct a randomized, double-blinded, sham-controlled trial of approximately 60 patients with minor stroke and post-stroke mild cognitive impairment (psMCI). Participants will be individually randomized on enrollment using a random number generator to treatment with anodal tDCS + computerized cognitive treatment (CCT) versus sham + CCT (approximately 30 patients in each arm). Clinical evaluation including assessment of cognition will be performed pre- and post-intervention by individuals on the study team blinded to the participant's intervention. Participants will also undergo functional neuroimaging with magnetoencephalography (MEG) pre- and post-intervention (1, 3, and 6 months post-stroke to evaluate for initial and longer-term effects of treatment on cerebral activation patterns and functional connectivity). Neuroimaging and clinical outcomes will be assessed to determine the effect of tDCS versus sham + CCT on psMCI.",[25,26,272],"Cognitive Impairment","2025-09-10",{"date":275,"type":32},"2025-09-16",{"date":277,"type":32},"2022-09-01",{"date":279,"type":21},"2027-08-31",{"name":38,"class":39},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":83,"phases":290,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":307},"100561670","efficacy-of-trans-spinal-magnetic-stimulation-on-functional-mobility-in-chronic-stroke-patients-100561670","NCT06593184","Efficacy of Trans-spinal Magnetic Stimulation on Functional Mobility in Chronic Stroke Patients","Inclusion Criteria:\n\n* Confirmation of Stroke by digital or physical imaging or medical report\n* Gait impairment\n* Stroke with at least 6 months after ictus\n\nExclusion Criteria:\n\n* Metallic implants in spinal cord\n* Major orthopedic\u002Frheumatological disorders\n* Incapacity of verbal or non-verbal communication","75 Years",{"count":289,"type":21},30,[85],"The goal of this clinical trial is to learn if trans-spinal magnetic stimulation works to treat gait disorders in chronic stroke adults. It will also learn about the safety of trans-spinal magnetic stimulation.\n\nThe main questions it aims to answer are:\n\nDoes trans-spinal magnetic stimulation enhance chronic stroke participants gait and functional mobility? Does the technique cause any side effects?\n\nResearchers will compare trans-spinal magnetic stimulation to a sham (a look-alike stimulation with no real effect) to see if trans-spinal magnetic stimulation works to treat gait disorders and improve functional mobility.\n\nParticipants will:\n\nReceive trans-spinal magnetic stimulation with treadmill training or a sham stimulation with treadmill training every day for 2 weeks.",[26,293,25],"Gait Disorders, Neurologic",[295,296,297,25],"Spinal cord","Magnetic Stimulation","Trans-spinal magnetic stimulation","2025-06-18",{"date":300,"type":32},"2025-06-24",{"date":302,"type":32},"2024-06-01",{"date":304,"type":21},"2025-08-01",{"name":306,"class":39},"Universidade Federal de Pernambuco",3,{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":287,"enrollmentInfo":316,"targetDuration":4,"studyType":83,"phases":317,"briefSummary":318,"conditions":319,"keywords":323,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":40},"100584872","transcutaneous-auricular-vagus-nerve-stimulation-in-patients-with-stroke-100584872","NCT06895005","Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Stroke","Effectiveness of Transcutaneous Auricular Vagus Nerve Stimulation on Upper Limb Motor Recovery After Stroke","INPULSE","Inclusion Criteria:\n\n* Age \\>18 years and \\\u003C75 years\n* Unilateral supratentorial ischemic stroke that occurred at least 7 days but not more 30 days before enrollment.\n* Modified Rankin Scale between 0 and 1 before stroke\n* Contralesional UL motor impairment defined by NIHSS item 5 score ≥ 1 to ≤ 3.\n* Ability to provide written informed consent.\n* Hemodynamically stable patients.\n* Patients residing in the metropolitan area of Bucaramanga.\n\nExclusion Criteria:\n\n* Significant cognitive or language impairment that would interfere with study participation or informed consent. This criterion will be defined by NIHSS item 1a-c score \\> 2, item 9 score \\> 1, item 11 score = 2.\n* Medical conditions that could interfere with study participation, for example ear infections or skin wounds.\n* Bradycardia (\\\u003C 50 bpm) or hypotension (\\\u003C 90\u002F60 mmHg)\n* Significant pre-existing disability\n* History of stroke\n* History of cardiac arrhythmia\n* History of severe head trauma, brain surgery, deep brain stimulation, or brain injuries of other etiologies.\n* Pregnant or planning on becoming pregnant or breastfeeding during the study period.\n* Medical or mental instability (diagnosis of personality disorder, psychosis, or substance abuse) that would prevent subject from meeting protocol timeline.\n* Subjects who are currently in another clinical trial or plan to do so during the study period.\n* Patient receiving any therapy at study entry that would interfere with VNS (e.g., drugs that interfere with neurotransmitter mechanisms: anticholinergics, adrenergic blockers, etc.).\n* Prior injury to vagus nerve.\n* Any other implanted device such as a pacemaker or other neurostimulator; any other investigational device or drug.",{"count":289,"type":21},[85],"This study will evaluate the effects of transcutaneous vagus nerve stimulation in combination with physical rehabilitation on upper limb motor function of patients with stroke.",[320,321,25,53,322],"Motor Impairment","Motor Impairments","Stroke, Ischemic",[25,324,325,326,246],"Vagus nerve","Vagus nerve stimulation","Transcutaneous vagus nerve stimulation","2025-03-25",{"date":329,"type":32},"2025-03-30",{"date":331,"type":21},"2025-04-01",{"date":333,"type":21},"2025-12-24",{"name":335,"class":39},"Fundación Cardiovascular de Colombia",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":40},"100578599","prevalence-of-central-neuropathic-pain-after-a-stroke-in-patients-attending-post-stroke-consultations-in-the-le-de-france-region-100578599","NCT06813391","Prevalence of Central Neuropathic Pain After a Stroke in Patients Attending Post-stroke Consultations in the Île-de-France Region","AVCD","Inclusion Criteria:\n\n* Patient aged ≥18 years\n* Patient attending a post-stroke consultation (3 to 6 months after the stroke)\n* Stroke confirmed by imaging (MRI or CT scan)\n* Francophone patient\n* Patient not opposing participation in the study\n\nExclusion Criteria:\n\n* Patient with cognitive or communication disorders preventing them from completing the questionnaires (as assessed by the investigator)\n* Patient under guardianship or curatorship\n* Patient deprived of liberty\n* Patient under judicial protection",{"count":344,"type":21},500,"Post-stroke pain is common, affecting 15-50% of patients and significantly impacting their quality of life, rehabilitation, and functional recovery. There are different types of post-stroke pain, including peripheral pain related to spasticity, shoulder pain, complex regional pain syndrome, and headaches, as well as central pain linked to brain lesions. Central Post-Stroke Pain (CPSP) is diagnosed when the pain has neuropathic characteristics (burning, cold, tightness, compression), possibly accompanied by allodynia, hyperesthesia, and sensory-motor disorders localized to the area affected by the stroke. CPSP disrupts sleep, impairs functional rehabilitation, and can lead to depression, anxiety, substance abuse, and cognitive disorders. The prevalence of CPSP varies, ranging from 1% to 35%, but it is likely underreported due to difficulties in detection caused by cognitive or communication issues, the clinical variability of CPSP, and its coexistence with other types of post-stroke pain.\n\nCPSP often remains resistant to standard neuropathic pain treatments, such as anticonvulsants and antidepressants, which may cause side effects that reduce patients' autonomy and quality of life. Non-pharmacological therapies used in other chronic pain conditions may offer promising alternatives, but have not been widely studied in CPSP. Improved clinical characterization of CPSP patients is essential. Following a 2015 decree by the French Ministry of Health, post-stroke consultations are standardized, providing a good opportunity for systematic pain screening. The study proposes a systematic screening of different types of pain during post-stroke consultations, categorizing patients into three groups: those with CPSP, those with pain from another mechanism, and those without pain.",[26,347],"Neuropathic Pain","2025-02-05",{"date":350,"type":32},"2025-02-07",{"date":352,"type":21},"2025-03-01",{"date":354,"type":21},"2026-10-01",{"name":356,"class":39},"Fondation Hôpital Saint-Joseph",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":365,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":83,"phases":369,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":40},"100573933","phase-2-intracerebral-autologous-stem-cell-therapy-for-chronic-stroke-patients-100573933","NCT06752720","Intracerebral Autologous Stem Cell Therapy for Chronic Stroke Patients","Intracerebral Autologous Mesenchymal Stem Cell Transplantation Therapy for Patients with Ischemic Stroke in Chronic Phase: Phase 2a Clinical Trial","RAINBOW-2a","Inclusion criteria\n\n1. Age between 20 and 70 years\n2. Clinical diagnosis of ischemic stroke between 6 months and 5 years ago\n3. Ischemic area in the territory of unilateral interanal cerebral artery\n4. Moderate to severe neurological symptoms; mRS 3 or 4, and Brunnstrom stage Ⅲ or IV\n5. Subjects with a DTI-RAINBOW (R-DTI) value of more than 70% at screening MR imaging\n6. No significant neurological impairment before the stroke (Pre-stroke mRS of 0 or 1)\n7. Subjects who can give informed consent by its self\n\nExclusion criteria\n\n1. Subject showing severe lower extremity contracture (Maximum knee extension less than -15 degrees, Maximum ankle flexion less than 0 degree)\"\n2. Anaemia (Hg \\\u003C 10·0 g\u002FdL)\n3. Thrombocytopaenia (platelet count \\\u003C 100,000\u002Fmm3)\n4. Severe heart disease (ischaemic heart disease, heart failure)\n5. Severe Systemic organ failure ALT \\\u003C3·0× upper limit of normal Total bilirubin \\\u003C 1·5× upper limit of normal Serum creatinine \\\u003C 1·5× upper limit of normal\n6. History of malignancy\n7. Carriers of infectious disease: syphilis, HBV, HCV, HIV-1\u002FHIV-2, HTLV-1, parvovirus B19\n8. Pregnant or lactating or expecting to become pregnant during the study\n9. Known serious allergy to any agents used in the study\n10. Contraindication for magnetic resonance imaging\n11. History of seizure within 2 years\n12. Subject's body weight less than 45 kg for male and 40kg for female \"13. Participating in another clinical trial within 90 days, or planning to participate in another clinical trial in the future\"\n\n14\\. Any condition that in the judgement of the investigator would place the patient at undue risk","20 Years","70 Years",{"count":368,"type":21},8,[188],"The goal of this clinical trial is to evaluate if autologous mesenchymal stem cell (HUNS001-01) transplantation therapy can provide neurological recovery in patients with chronic stage of stroke resulting in moderate to severe neurological sequelae. The main questions it aims to answer are:\n\nCan HUNS001-01 intracerebral transplantation demonstrate improvement in the mRS of disability for 1 year after intervention? Can HUNS001-01 intracerebral transplantation can be performed without any adverse events for 1 year after intervention?\n\nParticipants will receive the below interventions.\n\n* Screening for the eligibility to enroll the clinical trial (interview, blood test, imaging)\n* Harvest of platelet concentrates (PC)\n* Harvest of bone marrows (BM)\n* Receive intracerebral transplantation surgery of HUNS001-01\n* Post-operative rehabilitation\n* Follow-up studies (until 1 year or termination of the trial)",[25,322,53],[373,374,58,375],"stem cell therapy","mesenchymal stem cell","chronic","2025-01-22",{"date":378,"type":32},"2025-01-24",{"date":380,"type":32},"2024-12-01",{"date":382,"type":21},"2027-11-30",{"name":384,"class":39},"Hokkaido University Hospital",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":393,"targetDuration":395,"studyType":22,"phases":4,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":40},"100435896","data-collection-of-patients-admitted-to-the-stroke-unit-100435896","NCT04956185","Data Collection of Patients Admitted to the Stroke Unit","Prospective Data Collection of Patients Admitted to the Stroke Unit At University Hospital Ghent","PRODA-STROKE","Inclusion Criteria:\n\n* Patients admitted to the Stroke unit with a cerebrovascular disease\n* Patients admitted to the regular neurological ward or any other department in the University Hospital Ghent with a cerebrovascular disease who are actively followed by the department of Neurology during hospitalisation\n* Patients who have given their explicit informed consent for data collection\n\nExclusion Criteria:\n\n* Patients who have not given informed consent for data collection\n* Patients who are not able to give informed consent and whose legal representative has not given informed consent",{"count":394,"type":21},5000,"12 Months","The purpose of this prospective observational study is to create a database in which data will be collected from every patient admitted to the Stroke unit and who has explicitly given his or her informed consent for this data collection. The data that will be collected are part of the standard clinical data. No additional investigations, blood tests or any other tests will be performed. The purpose of this database is to conduct retrospective observational research in the future and will allow the hospital to keep track of some important quality indicators in stroke care.",[25,398,322,399,26],"Stroke, Acute","Stroke Hemorrhagic","2025-01-13",{"date":402,"type":32},"2025-01-15",{"date":404,"type":32},"2021-04-29",{"date":406,"type":21},"2031-02-01",{"name":408,"class":39},"University Hospital, Ghent",{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":83,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":40},"100520361","efficacy-of-rehabilitation-using-action-observation-and-muscle-stimulation-in-post-stroke-patients-100520361","NCT06055569","Efficacy of Rehabilitation Using Action Observation and Muscle Stimulation in Post-stroke Patients.","Efficacy of a Rehabilitation Treatment Using Observation THerapy Enhanced by MuscLe Synergy-derived ELectrical StimulatiOn in Post-stroke Patients (OTHELLO)","OTHELLO","Inclusion Criteria:\n\n* Age over 18 years;\n* Upper arm motor impairment after unilateral stroke as verified by MRI or CT;\n* Two weeks up to 6 months after stroke;\n* Grading of upper arm motor impairment\\>2 at Medical Research Council scale (MRC).\n\nExclusion Criteria:\n\n* Neurological\u002Forthopedic issues that would interfere with upper limb exercises;\n* Presence of any medical condition that represents a contraindication to Magnetic Resonance Imaging (MRI) examination or to Transcranial Magnetic Stimulation (TMS);\n* Presence of dermatologic issues that will interfere with neuromuscular stimulator;\n* Presence of electronic subcutaneous implants;\n* Presence of peripheral neuropathy;\n* Epilepsy;\n* Pregnancy;\n* Presence of severe cognitive impairment, including language comprehension detected during the neurological evaluation.",{"count":268,"type":21},[85],"Stroke is the third most common cause of disability worldwide and leads to upper limb motor disease in more than half of people affected.\n\nRecent data demonstrate that upper limb rehabilitation can be pursued using techniques such as the observation of action (Action Observation Therapy - AOT) or the stimulation of limb musculature using surface electrodes (Neuromuscular Electrical Stimulation - NMES).\n\nTo date, no rehabilitation studies used both the treatments (AOT-NMES) for the rehabilitation of upper limb after stroke.\n\nThe goal of this clinical trial is to study the efficacy of this combined approach (AOT-NMES) in people who developed upper limb motor impairment after stroke.\n\nThe main question this study aims to answer is if the rehabilitation performed using both action observation and neuromuscular stimulation has an higher efficacy than the use of AOT alone and higher than the observation of non-motor stimuli.\n\nParticipants will be people with upper limb impairment after stroke and will perform 15 rehabilitation sessions (5\u002Fweek, 3 weeks, 60 minutes each).\n\nEach participant will be casually included in one of following three rehabilitation groups:\n\n* Action observation associated with neuromuscular stimulation (AOT-NMES, experimental condition): they will observe upper limb movements while their arm muscles will be stimulated. After the observation phase they will try to perform the same movements with the impaired arm.\n* Action observation alone (AOT): subjects will observe upper limb movements and after the observation phase then they will try to execute them with the impaired arm.\n* Motor-neutral observation (MNO): subjects will observe non-movement videos and after the observation phase they will try to execute upper limb movements with the impaired arm.\n\nEach participant will be evaluated for motor function before and after rehabilitation treatment and researchers will compare the motion improvement between the groups to assess the efficacy of AOT-NMES over other treatments.",[25,26],"2024-11-11",{"date":423,"type":32},"2024-11-13",{"date":425,"type":32},"2023-11-01",{"date":427,"type":21},"2026-03-31",{"name":429,"class":39},"Fondazione Don Carlo Gnocchi Onlus",{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":83,"phases":441,"briefSummary":442,"conditions":443,"keywords":448,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":307},"100560284","associative-peripheral-stimulation-for-reduction-of-motor-impairment-during-acute-period-of-stroke-recovery-100560284","NCT06575140","Associative Peripheral Stimulation for Reduction of Motor Impairment During Acute Period of Stroke Recovery","Pilot Randomized Controlled Trial Assessing Associative Peripheral Stimulation (APS) for Reduction of Motor Impairment During Acute Period of Stroke Recovery","APS-PILOT","Inclusion Criteria:\n\n1. Confirmed ischemic or hemorrhagic stroke no earlier than 7 days prior to enrollment;\n2. Presentation of hemiparesis or paralysis of the upper extremity due to stroke;\n3. Ability to comprehend and follow study instructions;\n4. Ability to initiate finger extension (≥3°) at least three times per minute;\n5. Fugl-Meyer Assessment (Upper Extremity) score of \\\u003C47.\n\nExclusion Criteria:\n\n1. Contraindications, intolerance, or high sensitivity to the experimental protocol;\n2. History of upper-extremity disability prior to the index stroke;\n3. Neurological conditions (other than stroke) affecting motor function;\n4. Treatment of spasticity\u002Fincreased tone in the affected upper extremity (e.g., with Botox injection);\n5. Lack of access to a safe and suitable place of discharge for experimental sessions and follow-up visits.","79 Years",{"count":440,"type":21},20,[85],"Associative Peripheral Stimulation (APS) is a non-invasive therapy intended for stroke rehabilitation involving transcutaneous electrical muscle stimulation paired with voluntary movement. This pilot study investigates whether APS applied during the acute phase of stroke recovery may reduce impairment and improve function in the affected upper extremity.",[25,398,322,444,445,164,446,26,447],"Stroke, Hemorrhagic","Hemiparesis","Weakness of Extremities as Sequela of Stroke","Upper Extremity Paresis",[449,450],"Stroke Rehabilitation","Associative Peripheral Stimulation","2024-08-28",{"date":453,"type":32},"2024-08-30",{"date":455,"type":32},"2021-12-18",{"date":457,"type":21},"2024-12",{"name":459,"class":39},"Ahmed A. Rahim",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":16,"minAge":467,"maxAge":366,"enrollmentInfo":468,"targetDuration":4,"studyType":83,"phases":470,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":484,"locationsCount":40},"100506494","virtual-reality-versus-constraint-induced-movement-on-hemiparesis-in-cerebrovascular-event-100506494","NCT05875116","Virtual Reality Versus Constraint-induced Movement on Hemiparesis in Cerebrovascular Event","Effect of Different Therapeutic Modalities With Virtual Reality or Modified Constraint-induced Movement Therapy Compared With Usual Physical and Occupational Therapy on Motor Recovery of Paretic Limbs in Patients With Cerebrovascular Event","Inclusion Criteria:\n\n* Adult patients between 35 and 70 years of age and with a clinically and tomographically proven diagnosis of a cerebral vascular event in the territory of the middle cerebral artery.\n* Patients with hemiparesis secondary to the cerebrovascular event\n* Patients with a maximum Ashworth of 2 and Brunnstrom of minimum 4\n* Patients with or without aphasia\n* Patients with evolution between 1 to 3 months from hospital discharge of the cerebrovascular event\n* Patients with cerebrovascular event of any sex\n* Patients with vascular event without cognitive deficit\n* Patients who agree to participate by signing an informed consent, by them or their family member or person in charge.\n\nExclusion Criteria:\n\n* Patients who develop dementia or neurological-psychomotor complications during the study.\n* Patients who present a new cerebrovascular event during the investigation\n* Patients who do not complete at least 90% of the program\n* Patients in whom a lack of family support or secondary gain is detected.","35 Years",{"count":469,"type":21},119,[85],"The objective of this clinical trial is to measure the effect of Rehabilitation with Virtual Reality or Modified Constraint-Induced Movement Therapy on hemiparesis in patients with Cerebral Vascular Event.\n\nThe question to be answered is: What is the effect of different therapeutic modalities supported by Virtual Reality or Modified Constraint-Induced Movement Therapy compared with usual Physical and Occupational Therapy on motor recovery of paretic limbs in patients with Cerebrovascular Event?\n\nThe patients will carry out activities of:\n\n* Virtual reality or\n* Movement Restriction-Induction Therapy.\n\nThe investigators will compare the changes in the functionality of the paretic hemibody with a group undergoing regular physical and occupational therapy, as well as language and treatment-related satisfaction.",[26],[474,445,475,476,25,477],"Constraint-induced movement therapy","Neurorehabilitation","Satisfaction","Virtual Reality","2024-08-21",{"date":480,"type":32},"2024-08-23",{"date":482,"type":32},"2018-08-17",{"date":478,"type":21},{"name":485,"class":486},"Coordinación de Investigación en Salud, Mexico","OTHER_GOV",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":83,"phases":495,"briefSummary":496,"conditions":497,"keywords":502,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":4},"100559012","feasibility-and-potential-impact-of-an-individualized-exercise-program-via-a-telerehabilitation-device-in-chronic-patients-a-pilot-study-100559012","NCT06558591","Feasibility and Potential Impact of an Individualized Exercise Program Via a Telerehabilitation Device in Chronic Patients: A Pilot Study","Inclusion Criteria for professionals of exercise rehabilitation (ER):\n\n* Be a physiotherapist or kinesiologist working in the public sector, private sector, or in a mixed capacity,\n* Have been graduated for at least one year,\n* Conduct ER program with chronic patients and provide written consent.\n\nInclusion Criteria for chronic patients :\n\n* Be 18 years of age or older,\n* Be able to walk with or without assistives devices\n* Be capable of giving informed consent,\n* Be registered with the French health social security system,\n* Be under the care of a rehabilitation exercise professional.\n\nNon-inclusion criteria for patients :\n\n* Have an intolerance or inability to use digital tools,\n* Have a cognitive impairment,\n* Have contraindications to physical activity (unstable diabetes, unstable hypertension, unstable angina, intracardiac thrombus).",{"count":494,"type":21},50,[85],"Exercise Rehabilitation (ER) is widely used and effective in the treatment of chronic diseases; however, patients do not adhere to ER programs. Tele-rehabilitation is effective and often used to support and improve patient adherence. Thus, the ADEPINA device could be a promising solution for the individualized management of patients by their therapists. The aim of the study will be: a) To assess functional improvement, measured by the 6-minute walk test (6MWT) after the 12 weeks ER program in people with chronic disease. Additionally, the study will assess the individualized program' adherence and his effect on patients' physical fitness and quality of life. Methods: Fifty patients will follow individualized ER sessions to their patients (with chronic diseases) using the ADEPINA device, 2 to 3 times per week for 12 weeks. At the end of the intervention, the investigator will assess patients' lower limb strength (with sit to stand test), dynamic balance (Timed up and go test), patients' adherence to the ER program by evaluating the usage time of the system by participants, the treatment credibility and participant expectations for improvement will be assessed with the French version of the Credibility and Expectancy Questionnaire. The investigator will also evaluate the patients' quality of life (using the \"World Health Organization Quality of Life\" (WHOQOL) scale) at the beginning and end of the intervention. Discussion: This interventional pilot study could have positive impacts for participants and explore gaps in the current literature regarding the individualized telerehabilitation program' feasibility.",[498,499,26,500,501],"Chronic Disease","Chronic Condition","Age Problem","Parkinson Disease",[503,504,505,506,507],"Physical training","Telerehabilitation","Fitness test","health professional","chronic disease","2024-08-14",{"date":510,"type":32},"2024-08-16",{"date":512,"type":21},"2025-01",{"date":514,"type":21},"2027-07",{"name":516,"class":39},"Limoges University",{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":524,"targetDuration":4,"studyType":83,"phases":526,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":40},"100525454","safety-and-efficacy-study-of-implantable-neuromodulation-for-poststroke-hemiplegia-100525454","NCT06121947","Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia","Comparative Study of the Efficacy and Safety of Deep Brain Stimulation Versus Vagal Stimulation for Post-stroke Hemiplegia: Study Protocol for a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meet WHO or international diagnostic criteria for stroke disease;\n2. The first unilateral supratentorial ischemic or hemorrhagic stroke, the condition is stable after acute treatment of ischemic stroke, the course of disease is 6 months ≤ 1 year, and participate in 2 evaluations (screening and baseline) before enrollment.\n3. Diagnosed by professional physicians combined with brain CT or magnetic resonance imaging and other imaging techniques;\n4. Between the ages of 18 and 80, male or female\n5. The responsible lesion in the unilateral white matter area indicated by cranial CT or MRI\n6. Relevant sequelae such as limb dysfunction after stroke, accompanied by unilateral limb motor dysfunction, proved to be right-handed by standardized examination.\n7. National Institutes of Health Stroke Scale (NIHSS) score from 2 to 20, grades paralyzed muscle strength, between grades 1 and 4, WISCI II, grade \\>2 (0-20 items): Assisted by one or more persons, able to walk at least 10 m, and less responsive to conventional rehabilitation prior to inclusion.\n8. Perfect clinical data\n9. Stable medical and physical condition with adequate nursing support and appropriate medical care in the patient's home community.\n10. The patient himself or voluntarily signs the informed consent and is willing to cooperate with relevant treatmen\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GSC) score below 15, Minimum Mental State Examination (MMSE) assessment for dementia indicated, suffering from mental disturbance and unable to cooperate with examination or treatment.\n2. Motor and sensory disturbances are not induced by stroke, nor by previous ischemic stroke, but stroke induced by trauma, brain tumor, etc.\n3. Serious comorbidities, such as malignant tumors, primary heart, liver, kidney or hematopoietic system diseases.\n4. History of cognitive impairment, mental disorder, drug abuse, drug allergy, and alcoholism.\n5. Infection or rupture of the skin on the forearm or leg.\n6. Possess a pacemaker, metal stent, plate, or implant susceptible to electrical impulses in the body (pacemaker or defibrillator, baclofen pump, deep brain stimulator, Ventricular shunts, shrapnel, etc.).\n7. Pregnant or breast-feeding or have a recent birth plan.\n8. IS CLASSROUS.\n9. Congenital or acquired abnormalities of lower extremities (affecting joints and bones).\n10. Registration of investigators, their family members, employees, and other dependents.\n11. Severe joint contractures cause loss or limitation of lower limb activities.\n12. Blood system diseases with increased risk of bleeding during surgical intervention.\n13. Participate in another study drug study within 30 days before and during this study.\n14. Unable to complete the basic process, or difficult to maintain compliance and follow-up",{"count":525,"type":21},98,[85],"Background: Hemiplegia is a common complication after a stroke. Studies have shown that traditional medical and rehabilitation treatments are not good for improving patients' motor function, deep brain stimulation (DBS) and vagus nerve stimulation (VNS) can improve the motor function of patients, but there is no comparative study between them. Objectives: This study compares the efficacy and safety of DBS and VNS in the recovery of motor function in patients with post-stroke hemiplegia, determining the best treatment for patients with post-stroke hemiplegia, and providing high-level clinical evidence for patients and clinicians to choose from. Methods\u002FDesign: This is a randomized, double-blind, sham-controlled, cross-controlled pilot study. A total of 98 patients with post-stroke hemiplegia are assigned to receive DBS or VNS. After 3 and 6 months of follow-up, all the devices are turned off. After a 2-week washout, the control group is turned on, but the stimulation group is given sham stimulation. After 9 and 12 months of follow-up, all the devices are turned on. Then, at postoperative 15 and 18 months, postoperative neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Discussion: We propose a study design and rationale to compare the efficacy and safety of DBS and VNS in patients with post-stroke hemiplegia to provide evidence and reference for implantable neuromodulation in the treatment of post-stroke dysfunction, and to compare the therapeutic effects of DBS and VNS to provide evidence for patient and clinical diagnosis and treatment choices. Study limitations are related to the small sample size and short study period.",[26,529,530,531,25,532],"Deep Brain Stimulation","Vagus Nerve Stimulation","Motor Recovery","Hemiplegia","2023-11-02",{"date":535,"type":32},"2023-11-08",{"date":537,"type":21},"2023-11-10",{"date":539,"type":21},"2030-10-30",{"name":541,"class":39},"Chinese PLA General Hospital",{"id":543,"slug":544,"hasResults":11,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":549,"targetDuration":4,"studyType":83,"phases":551,"briefSummary":552,"conditions":553,"keywords":554,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":4},"100513651","efficacy-and-safety-of-deep-brain-stimulation-in-mesencephalic-locomotor-regionmlr-for-poststroke-hemiplegia-100513651","NCT05968248","Efficacy and Safety of Deep Brain Stimulation in Mesencephalic Locomotor Region（MLR） for Poststroke Hemiplegia","A Randomized Controlled Trial Exploring the Efficacy and Safety of Deep Brain Stimulation in the Treatment of Motor Dysfunction After Stroke#the PASTS-Stroke Study#","Inclusion Criteria:\n\n1. Meet WHO or international diagnostic criteria for stroke disease;\n2. The first unilateral supratentorial ischemic or hemorrhagic stroke, the condition is stable after acute treatment of ischemic stroke, the course of disease is 6 months ≤ 1 year, and participate in 2 evaluations (screening and baseline) before enrollment.\n3. Diagnosed by professional physicians combined with brain CT or magnetic resonance imaging and other imaging techniques;\n4. Between the ages of 18 and 80, male or female\n5. The responsible lesion in the unilateral white matter area indicated by cranial CT or MRI\n6. Relevant sequelae such as limb dysfunction after stroke, accompanied by unilateral limb motor dysfunction, proved to be right-handed by standardized examination.\n7. National Institutes of Health Stroke Scale (NIHSS) score from 2 to 20, grades paralyzed muscle strength, between grades 1 and 4, WISCI II, grade \\>2 (0-20 items): Assisted by one or more persons, able to walk at least 10 m, and less responsive to conventional rehabilitation prior to inclusion.\n8. Perfect clinical data\n9. Stable medical and physical condition with adequate nursing support and appropriate medical care in the patient's home community.\n10. The patient himself or voluntarily signs the informed consent and is willing to cooperate with relevant treatment\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GSC) score below 15, Minimum Mental State Examination (MMSE) assessment for dementia indicated, suffering from mental disturbance and unable to cooperate with examination or treatment.\n2. Motor and sensory disturbances are not induced by stroke, nor by previous ischemic stroke, but stroke induced by trauma, brain tumor, etc.\n3. Serious comorbidities, such as malignant tumors, primary heart, liver, kidney or hematopoietic system diseases.\n4. History of cognitive impairment, mental disorder, drug abuse, drug allergy, and alcoholism.\n5. Infection or rupture of the skin on the forearm or leg.\n6. Possess a pacemaker, metal stent, plate, or implant susceptible to electrical impulses in the body (pacemaker or defibrillator, baclofen pump, deep brain stimulator, Ventricular shunts, shrapnel, etc.).\n7. Pregnant or breast-feeding or have a recent birth plan.\n8. IS CLASSROUS.\n9. Congenital or acquired abnormalities of lower extremities (affecting joints and bones).\n10. Registration of investigators, their family members, employees, and other dependents.\n11. Severe joint contractures cause loss or limitation of lower limb activities.\n12. Blood system diseases with increased risk of bleeding during surgical intervention.\n13. Participate in another study drug study within 30 days before and during this study.\n14. Unable to complete the basic process, or difficult to maintain compliance and follow-up.",{"count":550,"type":21},62,[85],"Abstract: Background: The leftover movement disorder of stroke patients is one of the main causes of disability, and there is still no specific solution. Studies have shown that the improvement of movement disorder symptoms in patients receiving DBS is a potential therapy. treatment approach. However, at present, there are few large-sample studies in this area at home and abroad, which cannot well reveal its actual therapeutic effect and safety, and do not fully understand its potential neural mechanisms, so it is impossible to form a unified and standardized treatment standard, which limits its wide application in clinical practice. Objectives: This study aimed to determine the efficacy and safety of hemiplegia recovery after deep brain electrical stimulation in stroke patients with hemiplegia. Methods\u002FDesign: This was a double-blind randomized cross-over controlled pilot study in which 62 patients were assigned to receive deep brain stimulation (DBS) and randomized into DBS and control groups using a randomized controlled study approach, DBS group One month after the operation, electrical stimulation was started, and the control group was given sham stimulation treatment. After 3 and 6 months of follow-up, all the machines were turned off. After a 2-week washout period, the control group was turned on, but the DBS group was given sham stimulation. After the 9th and 12th month of follow-up, all patients were given start-up treatment, and neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Discussion: The investigators propose a research design and rationale to explore the effectiveness and safety of DBS in patients with post-stroke hemiplegia, and provide evidence and reference for DBS in the treatment of post-stroke dyskinesia. Study limitations are related to the small sample size and short study time period.",[26],[555,556,557,558],"Deep brain stimulation;","Hemiplegia;","Motor recovery;","Stroke.","2023-07-26",{"date":561,"type":32},"2023-08-01",{"date":563,"type":21},"2023-09-10",{"date":565,"type":21},"2027-11-11",{"name":541,"class":39},{"id":568,"slug":569,"hasResults":11,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":83,"phases":577,"briefSummary":579,"conditions":580,"keywords":585,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":594,"leadSponsor":596,"locationsCount":4},"100442801","phase-2-mlc1501-study-assessing-efficacy-in-stroke-recovery-100442801","NCT05046106","MLC1501 Study Assessing Efficacy in STROke Recovery","A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Efficacy and Safety Study of MLC1501 in Patients With Stroke","MAEStro","Inclusion Criteria:\n\n* Male or female.\n* 18 years old or older.\n* Diagnosed with acute ischemic stroke with compatible brain imaging findings between 2 days to 7 days prior to inclusion. Patients who undergo intravenous or endovascular thrombolysis or thrombectomy must be considered stable for at least 24 hours post-procedure prior to inclusion.\n* NIHSS total score of 8 to 18 (inclusive) at the time of inclusion with a combined score of at least 2 on the NIHSS motor items 5A or 5B and\u002For 6A or 6B.\n* A candidate for active rehabilitation in the opinion of the treating physician.\n* Able to comply with the requirements of the protocol and provide written informed consent by patient or legal representative before any study-specific procedure is performed.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin score of \\>1.\n* Contraindication to any of the study procedures.\n* Participation in another investigational drug or device trial within the past 30 days.\n* Intake of warfarin in the past one week or expected to be on warfarin while in the study.\n* Women who are pregnant, breastfeeding, of child-bearing potential or planning to become pregnant during the study. Menopausal\u002Fpost-menopausal women without menstruation for 12 consecutive months or surgically sterilized women may be included. Intake of oral contraceptive pills or hormone replacement therapy is not allowed. Use of mechanical barriers, e.g., condom, intrauterine device, are allowed. Local contraception requirements for clinical trials should be followed.\n* Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis, or members of the Fabaceae\u002FLeguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae\u002FUmbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip), or Quillaja bark (soapbark).\n* Evidence of other significant non-ischemic brain lesion which could affect long-term function or disability.\n* Evidence of advanced medical condition that would affect study assessment and follow-up, such as cancer, renal failure, liver cirrhosis, severe dementia, or psychosis.\n* Any other medical or psychiatric or cognitive condition which, in the study investigator's opinion, may jeopardize the patient by his\u002Fher participation in this study, may hamper his\u002Fher ability to complete procedures required in the study, affect study assessment and follow-up, or affect the validity of the study results",{"count":576,"type":21},540,[188,578],"PHASE3","This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.",[25,322,581,26,582,583,584],"Strokes Thrombotic","Stroke, Cardiovascular","Stroke, Embolic","Stroke, Cryptogenic",[586,587,573,588,589],"stroke","MLC1501","stroke recovery","neurorestoration","2023-03-14",{"date":592,"type":32},"2023-03-16",{"date":512,"type":21},{"date":595,"type":21},"2028-12",{"name":597,"class":598},"Moleac Pte Ltd.","INDUSTRY",{"id":600,"slug":601,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":607,"enrollmentInfo":608,"targetDuration":4,"studyType":83,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":73},"100406759","sedentarism-of-stroke-survivors-in-the-valencian-community-and-development-of-a-self-management-program-100406759","NCT04576598","Sedentarism of Stroke Survivors in the Valencian Community and Development of a Self-management Program","Assessment of the Level of Physical Activity and Sedentarism of Stroke Survivors in the Valencian Community and Development of a Specific Self-management Program","SEDMA_Stroke","Inclusion Criteria:\n\n* having sequelae after stroke of at least 6 months of evolution\n* being community-dwelling (minimum 2 months since the last stroke)\n* having the ability to walk around the house with or without technical aids but without requiring supervision from another person (FACHS ≥ 2)\n* having enough cognitive capacity to provide informed consent and to understand and answer the questions proposed\n\nExclusion Criteria:\n\n* not having a strength deficit in the lower limbs or walking difficulties\n* having poor vital prognosis or suffering from other pathologies or disorders that may alter the development of the study (blindness, severe sensitivity alteration, musculoskeletal or cardiovascular conditions that contraindicate the performance of physical activity...)","90 Years",{"count":609,"type":21},128,[85],"Stroke is the third leading cause of disability worldwide. Women present a higher incidence of this pathology and prevalence of its risk factors. Similarly, after stroke, women have a poorer functional outcome, higher rates of institutionalization and greater dependence on activities of daily living. People who have suffered a stroke are at increased risk of cardiovascular disease, with an estimated one-third of stroke survivors suffering a new event in the following 5 years. Current scientific literature recommends the promotion of physical activity (PA) and exercise for the prevention of stroke and its sequelae. However, stroke survivors are often insufficiently active. Therefore, changing their behavior with respect to PA and sedentary lifestyle is fundamental. Moreover, gender perspective, should also taken into account.\n\nThus, our aims are to study whether there are differences in women with chronic stroke sequelae compared to men in: 1) the amount of sitting time and its context, as well as the time spent in different intensities of PA; 2) the reduction of sitting time and its effect on health after the completion of the PA self-management program and sedentary lifestyle developed in this project; 3) the presence of sarcopenia, osteoporosis and the state of frailty.\n\nTo achieve these objectives, the lifestyle habits of 128 subjects (64 women) who live in the community and have chronic sequelae of stroke (≥ 6 months) will be evaluated. In addition, possible differences in the study variables will be verified with control people without sequelae of stroke. Moreover, in order to reduce the risks of stroke survivors, a program of self-management of PA and sedentary lifestyle will be developed. This program will be carried out through several sessions spread over six months that will incorporate: education, goal setting, identification of barriers, self-control and feedback. The feasibility of this intervention will be determined by examining compliance, duration, utility, and safety. At least 64 of the previously studied subjects will participate in this program, analyzing whether it favors the reduction of sitting time and its effect on health thanks to the measurement of different physical capacities. The differences between men and women in response to the program will be determined. Finally, we will explore whether the effect of the program is greater when it is implemented in the subacute than in the chronic phase.",[26],"2022-12-26",{"date":615,"type":32},"2022-12-28",{"date":617,"type":32},"2020-01-10",{"date":619,"type":21},"2026-12-20",{"name":621,"class":39},"University of Valencia"]